Homologous platelet concentrates: Products available and utilization rules in oncology and haematology;Concentrés plaquettaires homologues: Produits disponibles et règles d'utilisation en oncologie et hématologie

Hematologie

Volumn 10, Issue 3, 2004, Pages 233-244

  Folléa, Gilles ^a,b  

^a ETABLISSEMENT FRANÇAIS DU SANG   (France)

^b NONE   (France)

Author keywords

Haematology; Oncology; Platelet concentrates; Transfusion

Indexed keywords

THROMBOCYTE CONCENTRATE;

BLEEDING; BLOOD GROUP ABO INCOMPATIBILITY; FRANCE; HLA MATCHING; ONCOLOGY; REVIEW; RHESUS INCOMPATIBILITY; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOCYTOPHERESIS;

EID: 4043106197     PISSN: 12647527     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Gaydos LA, Freireich EJ, Mantel N. The quantitative relation between platelet count and hemorrhage in patients with accute leukemia. N Engl J Med 1962; 266: 905-9.
2. Slichter SJ, Harker LA. Thrombocytopenia: mechanisms and management of defects in platelet production. Clin Haematol 1978; 7: 523-39.
3. Blajchman MA. Substitutes and alternatives to platelet transfusions in thrombocytopenic patients. J Thromb Haemostas 2003; 1: 1637-41.
4. Agence française de sécurité sanitaire des produits de santé. Analyse du risque de transmission de la nouvelle variante de la maladie de Creutzfeldt-Jakob par le sang et ses dérivés. 2000. Disponible sur: http://www.afssaps.sante.fr, dans «Documentation et publications».
5. Agence française de sécurité sanitaire des praduits de santé. Transfusion de plaquettes: produits, indications. Résumé et argumentaire. 2003. Dispanible sur: http://www.afssaps. sante.fr, dans «Documentation et publications».
6. van Rhenen D, Gulliksson H, Cazenave JP, Pamphilon D, Ljungman P, Kluter H, Vermeij H, Klappers-Klume M, de Greef G, Lafaret M, Lioure B, Davis K, Marblie S, Mayaudon V, Flament J, Conlan M, Lin L, Metzel P, Buchholz D, Corash L. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003; 101: 2426-33.
7. Pillonel J, Laperche S, Saura C, Desenclas JC, Courouce AM. Transfusion-Transmissible Agents Working Group of the French Society of Blood Transfusion. Trends in residual risk of transfusion-transmitted viral infections in France between 1992 and 2000. Transfusion 2002; 42: 980-8.
8. Anderson NA, Gray S, Copplestone JA, Chan DC, Hamon M, Prentice AG, Johnson SA, Phillips M, Van Waeg G, Oakhill A, Abeyasekera S, Pamphilon DH. A prospective randomized study of three types of platelet concentrates in patients with haematological malignancy: corrected platelet count increments and frequency of nonhaemolytic febrile transfusion reactions. Transfus Med 1996; 6: 33-9.
9. Perez P, Salmi R, Follea G, Schmit JL, de Barbeyrac B, Sudre Ph, Salamon R. Determinants of transfusion-associated bacterial contamination: results of the French BACTHEM case-control study. Transfusion 2001; 41: 862-72.
10. Kuehnert MJ, Roth VR, Haley NR, Gregory KR, Elder KV, Schreiber GB, Arduino MJ, Holt SC, Carson LA, Banerjee SN, Jarvis WR. Transfusion-transmitted bacterial infection in the United States, 1998 through 2000. Transfusion 2001; 41: 1493-9.
11. The trial to reduce alloimmunization to platelets study group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997; 337: 1861-9.
12. Hogge DE, Dutcher JP, Aisner J, Schiffer CA. Lymphocytotoxic antibody is a predictor of response to random donor platelet transfusion. Am J Hematol 1983; 14: 363-9.
13. Klingemann HG, Self S, Banaji M, Deeg HJ, Daney K, Slichter SJ, Thomas ED, Storb R. Refractoriness to random donor platelet transfusions in patients with aplastic anaemia: a multivariate analysis of data from 264 cases. Br J Haematol 1987; 66: 115-21.
14. Yankee RA, Graff KS, Dowling R, Henderson ES. Selection of unrelated compatible platelet donors by lymphocyte HL-A matching. N Engl J Med 1973; 288: 760-4.
15. Duquesnoy RJ, Filip DJ, Rodey GE, Rimm AA, Aster RH. Successful transfusion of platelets "missmatched" far HLA antigens to alloimmunized thrombocytopenic patients. Am J Hematol 1977; 2: 219-26.
16. Freedman J, Garvey MB, Salomon de Friedberg Z, Hornstein A, Blanchette V. Random donor platelet crossmatching: comparison of four platelet antibody detection methods. Am J Hematol 1988; 28: 1-7.
17. Petz LD, Garratty G, Calhoun L, Clark BD, Terasaki PI, Gresens C, Garnbein JA, Landaw EM, Smith R, Cecka M. Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity. Transfusion 2000; 40: 1446-56.
18. Engelfriet CP, Reesink HW, Lee K, Taaning E, Zupanska B, Kurz M, Shibata Y, Nelson KA, Kekomäki R, Sanz C, Kiefel V, Brand A, Novarrete C. Detection of platelet-reactive antibodies in patients who are refractory to platelet transfusion, and the selection of compatible donors. Vox Sang 2003; 84: 73-88.
19. Despotis GJ, Goodnough LT, Dynis M, Baorto D, Spitznagel E. Adverse events in platelet apheresis donors: a multivariate analysis in a hospital-based program. Vax Sang 1999; 77: 24-32.
20. Popovsky MA, Whitaker B, Arnold NL. Severe outcomes of allogeneic and autologous blood donation: frequency and characterization. Transfusion 1995; 35: 734-7.
21. Lapez-Plaza I, Weissfeld J, Triulzi DJ. The cost-effectiveness of reducing donor exposures with single-donor versus pooled random-donor platelets. Transfusion 1999; 39: 925-32.
22. Blajchman MA, Goldman M, Freedman JJ, Sher GD. Proceedings of a consensus conference: prevention of post-transfusion CMV in the era of universal leukoreduction. Transfus Med Rev 2001; 15: 1-20.
23. Nichols WG, Price TH, Gooley T, Corey L, Boeckh M. Transfusion - transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood 2003; 101: 4195-200.
24. Wagner T, Vetter A, Dimovic N, Guber SE, Helmberg W, Kröll W, Lanzer G, Mayr WR, Neumüller J. Ultrastructural changes and activation differences in platelet concentrates stored in plasma and additive solution. Transfusion 2002; 42: 719-27.
25. Norol F, Bierling P, Roudot-Thoraval F, Le Cœur FF, Rieux C, Lavaux A, Kuentz M, Duedari N. Platelet transfusion: a dose response study. Blood 1998; 92: 1448-53.
26. Klumpp TR, Herman JH, Gaughan JP, Russo RR, Christman RA, Goldberg SL, Ackerman SJ, Bleecker GC, Mangan KF Clinical consequences of alterations in platelet transfusion dose: a prospective, randomised, double-blind trial. Transfusion 1999; 39: 674-81.
27. Peter-Salonen K, Bucher U, Nydegger UE. Comparison of posttransfusion recoveries achieved with either fresh or stored platelet concentrates. Blut 1987; 54: 207-12.
28. Norol F, Kuentz M, Cordonnier C, Beoujean F, Haioun C, Vernant JP, Duedari N. Influence of clinical status on the efficiency of stored platelet transfusion. Br J Haematol 1994; 86: 125-9.
29. Heal JM, Blumberg N, Masel D. An evaluation of crossmatching, HLA, and ABO matching for platelet transfusions to refractory patients. Blood 1987; 70: 23-30.
30. Jiménez TM, Patel SB, Pineda AA, Tefferi A, Owen WG. Factors that influence platelet recovery after transfusion: resolving donor quality from ABO compatibility. Transfusion 2003; 43: 328-34.
31. Heol JM, Kenmotsu N, Rowe JM, Blumberg N. A possible survival advantage in adults with acute leukemia receiving ABO-identical platelet transfusions. Am J Hematol 1994; 45: 189-90.
32. Heal JM, Blumberg N. The second century of ABO: and now for something completely different. Transfusion 1999; 39: 1155-9.
33. Benjamin RJ, Antin JH. ABO-incompatible bone marrow transplantation: the transfusion of incompatible plasma may exacerbate regimen-related toxicity. Transfusion 1999; 39: 1273-4.
34. Atoyebi W, Mundy N, Croxton T, Littlewood TJ, Murphy MF. Is it necessary to administer anti-D to prevent RhD immunization after the transfusion of RhD-positive platelet concentrates ? Br J Haematol 2000; 111: 980-3.
35. Cid J, Ortin W, Elies E, Castellà D, Panadés M, Martin-Vega C. Absence of anti-D alloimmunization in hematologic patients after D-incompatible platelet transfusions. Transfusion 2002; 42: 173-6.
36. Menitove JE. Immunoprophylaxis for D- patients receiving platelet transfusions from D + donors ? Transfusion 2002; 42: 136-8.
37. Heckman KD, Weiner GJ, Davis CS, Strauss RG, Jones MP, Burns CP. Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10 000/μL versus 20 000/μL. J Clin Oncol 1997; 15: 1143-9.
38. Rebulla P, Finazzi G, Marangoni F, Avvisati G, Gugliotta L, Tognoni G, Barbui T, Mandelli F, Sirchia G. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. N Eng J Med 1997; 337: 1870-5.
39. Gmür J, Burger J, Schanz U, Fehr J, Schaffner A. Safety of stringent prophylactic platelet transfusion policy for patients with acute leukoemia. Lancet 1991; 328: 1223-6.
40. 9/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood 1998; 91: 3601-6.
41. Heddle NM, Cook RJ, Webert KE, Sigouin C, Rebulla P in collaboration with the biomedical excellence for safer transfusion (BEST) working party of the international society for blood transfusion. Methodologic issues in the use of bleeding as an outcome in transfusion medicine studies. Transfusion 2003; 43: 742-52.
42. Corash L. How much do we know about the platelet transfusion threshold ? Transfusion 2003; 43: 691-3.
43. Bishop JF, McGrath K, Wolf MM, Matthews JP, De Luise T, Holdsworth R, Yuen K, Veale M, Whiteside MG, Cooper IA, Szer J. Clinical factors influencing the efficacy of pooled platelet transfusions. Blood 1988; 71: 383-7.
44. A1 - negative platelets. Transsion 1990; 30: 433-5.
45. Win N, Peterkin MA, Watson WH. The therapeutic value of HPA-1a-negative platelet transfusion in post-transfusion purpura complicated by life-threatening haemorrhage. Vox Sang 1995; 69: 138-9.